All Articles

Docusign aims to expand beyond e-signatures with its Intelligent Agreement Management platform, facing growing competition and economic headwinds. Analysts weigh in on the company’s strategy and future outlook.

Texas coffee chain Merit Coffee is dedicating a day of sales to support Austin and Dallas-area organizations tackling homelessness and food insecurity. Learn more about the impact and the charities benefiting from the initiative.

As SSA recovers from shutdowns, disability claimants face hurdles. Allsup offers expert aid, highlighting the critical role of representation in securing vital benefits.

Canadian biotech Appili Therapeutics is doubling down on a unique strategy – securing government grants and contracts to fund its infectious disease research, aiming to minimize shareholder dilution and address critical unmet medical needs.

Escalating insurance premiums are crippling the trucking industry, even as safety technology improves and accident rates stabilize. A new ATRI study aims to uncover solutions to this growing crisis.

Data from Phase 1 trials suggest SAB-142 could offer a new approach to treating Type 1 Diabetes, potentially preserving insulin-producing cells without prolonged immunosuppression. The company is now advancing into a pivotal Phase 2b trial.

A growing partnership between a credit union, university, and athletic brand is making a tangible difference in the lives of Phoenix-area students, providing not just footwear, but a foundation for success.

Positive early trial data for Aptose Biosciences’ acute myeloid leukemia treatment, tuspetinib, is tempered by ongoing financial challenges and reliance on a single funding source. Can the biotech survive long enough to bring its therapy to market?

Senti Bio presents encouraging Phase 1 data for its novel AML therapy, SENTI-202, but faces a critical funding shortfall. Can this innovative gene-circuit technology overcome significant financial headwinds?

Positive Phase 2 data for Alumis’s envudeucitinib offers a new potential treatment for psoriasis, with a focus on selective TYK2 inhibition. The drug is poised to compete with established biologics and emerging oral therapies.

Clinical trial advancements and a robust platform for drug discovery position Acrivon Therapeutics as a key player in precision oncology. New data offers hope for patients battling endometrial cancer.

As housing costs rise, manufactured home investor FG Communities expands its footprint in North Carolina, providing crucial affordable options near the major military base of Camp Lejeune. Is this a model for addressing the nation's housing crisis?

GoPro's CEO just made a significant personal investment in the company, signaling confidence in its diversification strategy. But with rivals like DJI launching competitive products, can GoPro maintain momentum?

Biotech firm Trevi Therapeutics reports strong Q3 financials and positive clinical trial data, paving the way for potential first-in-class treatment for chronic cough conditions like IPF and RCC.

Biotech firm Calidi Biotherapeutics reports positive preclinical results for its RedTail platform and lead candidate, CLD-401, alongside a successful funding round. The company aims to revolutionize cancer treatment through systemic targeted genetic medicine delivery.

Aardvark Therapeutics reports positive clinical trial progress for its Prader-Willi Syndrome treatment and unveils promising preclinical data for a novel obesity candidate designed to address limitations of existing GLP-1 RA therapies.

After navigating financial headwinds, Evofem Biosciences reports positive Q3 results, fueled by cost reductions and strategic shifts. Can the company maintain momentum and expand access to critical women’s health solutions?

Biotech firm Equillium has secured up to $50 million in funding to advance its lead candidate, EQ504, a novel therapy targeting ulcerative colitis. The company is betting on a new approach to immune modulation, shifting focus from previous programs.

Molecular diagnostics firm Co-Diagnostics reports widening losses and introduces a non-GAAP metric to assess performance, raising questions about its long-term viability as COVID-19 testing demand wanes.

Pittsburgh is betting on technology to boost its population. A new platform, 'Pittsburgh Tomorrow Pioneer,' uses AI to connect newcomers with resources, aiming to make the city a welcoming hub.